Press releases

Regulatory

December 28, 2020

Oasmia’s partner Elevar Therapeutics signs licensing agreement with Inceptua Group for the commercialization of Apealea® (paclitaxel micellar) in Europe

Regulatory

December 9, 2020

Interim report¹ for the period May 1, 2020 – October 31, 2020

Regulatory

December 3, 2020

Oasmia’s Partner Elevar Provides an Update on Apealea Development Plans in Ovarian Cancer

Regulatory

November 20, 2020

Nomination Committee appointed for the 2021 Annual General Meeting in Oasmia

Regulatory

October 14, 2020

The Disciplinary Committee of Nasdaq Stockholm orders Oasmia to pay a fine

Regulatory

October 5, 2020

Oasmia’s partner Elevar Therapeutics signs agreement with Taiba Middle East FZ LLC for commercialization of Apealea® in the Middle East and North Africa Region

Regulatory

September 25, 2020

Oasmia Brings an Action against the Former Board of Directors

Regulatory

September 9, 2020

Report from Annual General Meeting of Oasmia Pharmaceutical AB

Regulatory

September 9, 2020

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2020

Regulatory

September 8, 2020

Oasmia Pharmaceutical Appoints Fredrik Järrsten as Chief Financial Officer

Regulatory

September 2, 2020

Oasmia’s Nomination Committee revises its proposal for the AGM regarding Board of Directors

Regulatory

August 31, 2020

CFO of Oasmia, Michael af Winklerfelt has resigned

Regulatory

August 19, 2020

Oasmia publishes its annual report

Regulatory

August 10, 2020

Notice of Annual General Meeting in Oasmia Pharmaceutical AB

Regulatory

July 27, 2020

Oasmia’s partner Elevar Therapeutics and Tanner Pharma Announce Global Named Patient Program to Provide Access to Apealea®

Regulatory

June 18, 2020

Oasmia Pharmaceutical AB (publ). Year-end report for the financial year May 1, 2019 – April 30, 2020

Regulatory

May 14, 2020

Oasmia Pharmaceutical supplements bulletin from Extraordinary General Meeting

Regulatory

May 14, 2020

Oasmia Pharmaceutical Announces Results of Extraordinary General Meeting and Board Changes

Regulatory

May 13, 2020

Oasmia announces outcome of strategic review to deliver long-term, profitable growth as a specialty pharma company

Regulatory

April 17, 2020

Notice of extraordinary general meeting in Oasmia Pharmaceutical AB

Regulatory

April 17, 2020

Oasmia Nomination Committee suggest changes in the Board of Directors

Regulatory

March 27, 2020

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1, 2019 – January 31, 2020

Regulatory

March 25, 2020

Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea® with an upfront payment of USD 20 million, milestone payments with a potential of up to USD 678 million and double digit royalties.

Regulatory

February 14, 2020

Oasmia appoints new CEO